Role of short-chain fatty acids in colonic inflammation, carcinogenesis, and mucosal protection and healing

Nutrition Reviews

Volumn 75, Issue 4, 2017, Pages 286-305

  van der Beek, Christina M ^a,b   Dejong, Cornelis H C ^a,b   Troost, Freddy J ^a,b   Masclee, Ad A M ^a,b   Lenaerts, Kaatje ^a,b  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Carcinogenesis; Inflammation; Mucosal healing; Short chain fatty acids

Indexed keywords

SHORT CHAIN FATTY ACID; VOLATILE FATTY ACID;

ARTICLE; COLITIS; COLON CARCINOGENESIS; COLON MUCOSA; CROHN DISEASE; DIET SUPPLEMENTATION; EPIDEMIOLOGICAL DATA; FATTY ACID TRANSPORT; HEALING; HOMEOSTASIS; HUMAN; ILEITIS; METABOLISM; MOLECULAR MECHANICS; NONHUMAN; PHYSIOLOGY; PROCTITIS; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION; ULCERATIVE COLITIS; ANIMAL; COLON; COLON TUMOR; INFLAMMATION; INTESTINE MUCOSA;

ANIMALS; COLON; COLONIC NEOPLASMS; FATTY ACIDS, VOLATILE; HUMANS; INFLAMMATION; INTESTINAL MUCOSA;

EID: 85021180814     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/nutrit/nuw067     Document Type: Article

References (243)

1. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:968-984.
2. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81:1031-1064.
3. Wong JM, de Souza R, Kendall CW, et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235-243.
4. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev. 1990;70:567-590.
5. Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27:104-119.
6. Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17:1519-1528.
7. Koh A, De Vadder F, Kovatcheva-Datchary P, et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332-1345.
8. Boets E, Gomand SV, Deroover L, et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. J Physiol. 2017:595:541-555.
9. Wolever TM, Spadafora P, Eshuis H. Interaction between colonic acetate and propionate in humans. Am J Clin Nutr. 1991;53:681-687.
10. den Besten G, Lange K, Havinga R, et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol. 2013;305:G900-G910.
11. Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28:1221-1227.
12. Ahmed R, Segal I, Hassan H. Fermentation of dietary starch in humans. Am J Gastroenterol. 2000;95:1017-1020.
13. Cummings JH, Macfarlane GT. Colonic microflora: nutrition and health. Nutrition. 1997;13:476-478.
14. Argenzio RA, Southworth M. Sites of organic acid production and absorption in gastrointestinal tract of the pig. Am J Physiol. 1975;228:454-460.
15. Vogt JA, Wolever TM. Fecal acetate is inversely related to acetate absorption from the human rectum and distal colon. J Nutr. 2003;133:3145-3148.
16. van der Beek CM, Bloemen JG, van den Broek MA, et al. Hepatic uptake of rectally administered butyrate prevents an increase in systemic butyrate concentrations in humans. J Nutr. 2015;145:2019-2024.
17. Bloemen JG, Venema K, van de Poll MC, et al. Short chain fatty acids exchange across the gut and liver in humans measured at surgery. Clin Nutr. 2009;28:657-661.
18. Cummings JH. Colonic absorption: the importance of short chain fatty acids in man. Scand J Gastroenterol Suppl. 1984;93:89-99.
19. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 2004;447:619-628.
20. Harig JM, Ng EK, Dudeja PK, et al. Transport of n-butyrate into human colonic luminal membrane vesicles. Am J Physiol. 1996;271(3, pt 1):G415-G422.
21. +-coupled transporter for short-chain fatty acids. J Biol Chem. 2004;279:13293-13296.
22. Tyagi S, Venugopalakrishnan J, Ramaswamy K, et al. Mechanism of n-butyrate uptake in the human proximal colonic basolateral membranes. Am J Physiol Gastrointest Liver Physiol. 2002;282:G676-G682.
23. Gill RK, Saksena S, Alrefai WA, et al. Expression and membrane localization of MCT isoforms along the length of the human intestine. Am J Physiol Cell Physiol. 2005;289:C846-C852.
24. Brown AJ, Goldsworthy SM, Barnes AA, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278:11312-11319.
25. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003;278:25481-25489.
26. Tazoe H, Otomo Y, Kaji I, et al. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol. 2008;59(suppl 2): 251-262.
27. Tazoe H, Otomo Y, Karaki S, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res. 2009;30:149-156.
28. Kim MH, Kang SG, Park JH, et al. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013;145:396-406.
29. Thangaraju M, Cresci GA, Liu K, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009;69:2826-2832.
30. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;40:128-139.
31. Sterner R, Vidali G, Allfrey VG. Studies of acetylation and deacetylation in high mobility group proteins. Identification of the sites of acetylation in high mobility group proteins 14 and 17. J Biol Chem. 1981;256:8892-8895.
32. Clausen MR, Mortensen PB. Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. Gut. 1995;37:684-689.
33. Hague A, Elder DJ, Hicks DJ, et al. Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer. 1995;60:400-406.
34. Comalada M, Bailon E, de Haro O, et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol. 2006;132:487-497.
35. Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980;316:712-715.
36. Mortensen FV, Nielsen H, Mulvany MJ, et al. Short chain fatty acids dilate isolated human colonic resistance arteries. Gut. 1990;31:1391-1394.
37. Mortensen FV, Hessov I, Birke H, et al. Microcirculatory and trophic effects of short chain fatty acids in the human rectum after Hartmann's procedure. Br J Surg. 1991;78:1208-1211.
38. Kvietys PR, Granger DN. Effect of volatile fatty acids on blood flow and oxygen uptake by the dog colon. Gastroenterology. 1981;80(5 pt 1):962-969.
39. Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabol. 2011;13:517-526.
40. Elamin EE, Masclee AA, Dekker J, et al. Short-chain fatty acids activate AMPactivated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. J Nutr. 2013;143:1872-1881.
41. Peng L, Li ZR, Green RS, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139:1619-1625.
42. Peng L, He Z, Chen W, et al. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;61: 37-41.
43. Suzuki T, Yoshida S, Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr. 2008;100: 297-305.
44. Correa-Oliveira R, Fachi JL, Vieira A, et al. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. 2016;5:e73. doi:10.1038/cti.2016.17.
45. Terzi C, Sevinc AI, Kocdor H, et al. Improvement of colonic healing by preoperative rectal irrigation with short-chain fatty acids in rats given radiotherapy. Dis Colon Rectum. 2004;47:2184-2194.
46. Kripke SA, Fox AD, Berman JM, et al. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN J Parenter Enteral Nutr. 1989;13:109-116.
47. Wilson AJ, Gibson PR. Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. Gastroenterology. 1997;113:487-496.
48. Aguilar-Nascimento JE, Franca-da-Silva LR, De-Oliveira AF, et al. Enhanced mucosal re-epithelialization induced by short chain fatty acids in experimental colitis. Braz J Med Biol Res. 1999;32:961-966.
49. Sakata T. Effects of indigestible dietary bulk and short chain fatty acids on the tissue weight and epithelial cell proliferation rate of the digestive tract in rats. J Nutr Sci Vitaminol (Tokyo). 1986;32:355-362.
50. Aguilar-Nascimento JE, Oliveira-Neto JP, Mathie RT, et al. Effect of intraoperative nutritional solutions on perianastomotic colonic mucosa in experimental large bowel obstruction. Dig Dis Sci. 1997;42:2581-2584.
51. Dhawan P, Singh AB, Deane NG, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005;115:1765-1776.
52. Gecse K, Roka R, Sera T, et al. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion. 2012;85: 40-46.
53. Den Hond E, Hiele M, Evenepoel P, et al. In vivo butyratemetabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology. 1998;115:584-590.
54. Burger-van Paassen N, Vincent A, Puiman PJ, et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J. 2009;420:211-219.
55. Tytgat KM, Opdam FJ, Einerhand AW, et al. MUC2 is the prominent colonic mucin expressed in ulcerative colitis. Gut. 1996;38:554-563.
56. Buisine MP, Desreumaux P, Leteurtre E, et al. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut. 2001;49:544-551.
57. Willemsen LE, Koetsier MA, van Deventer SJ, et al. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E1 and E2 production by intestinal myofibroblasts. Gut. 2003;52:1442-1447.
58. Augenlicht L, Shi L, Mariadason J, et al. Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. Oncogene. 2003;22:4983-4992.
59. Hatayama H, Iwashita J, Kuwajima A, et al. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. Biochem Biophys Res Commun. 2007;356:599-603.
60. Finnie IA, Dwarakanath AD, Taylor BA, et al. Colonic mucin synthesis is increased by sodium butyrate. Gut. 1995;36:93-99.
61. Gaudier E, Rival M, Buisine MP, et al. Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. Physiol Res. 2009;58:111-119.
62. Hoebler C, Gaudier E, De Coppet P, et al. MUC genes are differently expressed during onset and maintenance of inflammation in dextran sodium sulfatetreated mice. Dig Dis Sci. 2006;51:381-389.
63. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211-214.
64. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory
65. Leufkens AM, van Duijnhoven FJ, Woudt SH, et al. Biomarkers of oxidative stress and risk of developing colorectal cancer: a cohort-nested case-control study in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol. 2012;175:653-663.
66. Russo I, Luciani A, De Cicco P, et al. Butyrate attenuates lipopolysaccharideinduced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery. PLoS One. 2012;7:e32841. doi:10.1371/ journal.pone.0032841.
67. Hamer HM, Jonkers DM, Vanhoutvin SA, et al. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr. 2010;29:738-744.
68. Zhu H, Li YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med (Maywood). 2012;237:474-480.
69. Abrahamse SL, Pool-Zobel BL, Rechkemmer G. Potential of short chain fatty acids to modulate the induction of DNA damage and changes in the intracellular calcium concentration by oxidative stress in isolated rat distal colon cells. Carcinogenesis. 1999;20:629-634.
70. Rosignoli P, Fabiani R, De Bartolomeo A, et al. Protective activity of butyrate on hydrogen peroxide-induced DNA damage in isolated human colonocytes and HT29 tumour cells. Carcinogenesis. 2001;22:1675-1680.
71. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181-193.
72. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785-3789.
73. Jahns F, Wilhelm A, Jablonowski N, et al. Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue. Carcinogenesis. 2011;32:913-920.
74. Tong X, Yin L, Giardina C. Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem Biophys Res Commun. 2004;317:463-471.
75. Crew TE, Elder DJ, Paraskeva C. A cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis. 2000;21:69-77.
76. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxiainducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098-1106.
77. Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17:662-671.
78. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978;14:105-113.
79. Macia L, Thorburn AN, Binge LC, et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev. 2012;245:164-176.
80. Zimmerman MA, Singh N, Martin PM, et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fasmediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1405-G1415.
81. Chang PV, Hao L, Offermanns S, et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA. 2014;111:2247-2252.
82. Saemann MD, Bohmig GA, Osterreicher CH, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and upregulation of IL-10 production. FASEB J. 2000;14:2380-2382.
83. Tedelind S, Westberg F, Kjerrulf M, et al. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007;13:2826-2832.
84. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446-450.
85. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451-455.
86. Kim M, Qie Y, Park J, et al. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe. 2016;20:202-214.
87. Segain JP, Raingeard de la Bletieŕe D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFjB inhibition: implications for Crohn's disease. Gut. 2000;47:397-403.
88. Vinolo MA, Rodrigues HG, Nachbar RT, et al. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3:858-876.
89. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.
90. Cox MA, Jackson J, Stanton M, et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines. World J Gastroenterol. 2009;15:5549-5557.
91. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569-573.
92. Hinnebusch BF, Meng S, Wu JT, et al. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr. 2002;132:1012-1017.
93. Daly K, Shirazi-Beechey SP. Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol. 2006;25:49-62.
94. Emenaker NJ, Calaf GM, Cox D, et al. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J Nutr. 2001;131(11 suppl):3041S-3046S.
95. Thangaraju M, Cresci G, Itagaki S, et al. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J Gastrointest Surg. 2008;12:1773-1781; discussion 1781-1772.
96. Vecchia MG, Carnelos Filho M, Fellipe CR, et al. Acetate and propionate potentiate the antiproliferative effect of butyrate on RBL-2H3 growth. Gen Pharmacol. 1997;29:725-728.
97. Fu H, Shi YQ, Mo SJ. Effect of short-chain fatty acids on the proliferation and differentiation of the human colonic adenocarcinoma cell line Caco-2. Chin J Dig Dis. 2004;5:115-117.
98. Butt AJ, Hague A, Paraskeva C. Butyrate- but not TGFbeta1-induced apoptosis of colorectal adenoma cells is associated with increased expression of the differentiation markers E-cadherin and alkaline phosphatase. Cell Death Differ. 1997;4:725-732.
99. Barshishat M, Polak-Charcon S, Schwartz B. Butyrate regulates E-cadherin transcription, isoform expression and intracellular position in colon cancer cells. Br J Cancer. 2000;82:195-203.
100. Zuo L, Lu M, Zhou Q, et al. Butyrate suppresses proliferation and migration of RKO colon cancer cells though regulating endocan expression by MAPK signaling pathway. Food Chem Toxicol. 2013;62:892-900.
101. Krishnan M, Singh AB, Smith JJ, et al. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene. 2010;29:305-312.
102. Tang Y, Chen Y, Jiang H, et al. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int J Cancer. 2011;128:847-856.
103. Bordonaro M, Lazarova DL, Sartorelli AC. The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res. 2007;313:1652-1666.
104. Lazarova DL, Bordonaro M, Carbone R, et al. Linear relationship between Wnt activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate. Int J Cancer. 2004;110:523-531.
105. Gibson PR, Moeller I, Kagelari O, et al. Contrasting effects of butyrate on the expression of phenotypic markers of differentiation in neoplastic and nonneoplastic colonic epithelial cells in vitro. J Gastroenterol Hepatol. 1992;7:165-172.
106. Donohoe DR, Collins LB, Wali A, et al. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 2012;48:612-626.
107. Singh B, Halestrap AP, Paraskeva C. Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Carcinogenesis. 1997;18:1265-1270.
108. Kaiko GE, Ryu SH, Koues OI, et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell. 2016;165:1708-1720.
109. Malago JJ, Sangu CL. Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats. J Zhejiang Univ Sci B. 2015;16:224-234.
110. Moeinian M, Ghasemi-Niri SF, Mozaffari S, et al. Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis.World J Gastroenterol. 2014;20:10876-10885.
111. Ferreira TM, Leonel AJ, Melo MA, et al. Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-fluorouracil administration. Lipids. 2012;47:669-678.
112. Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J. 2006;82:130-135.
113. Venkatraman A, Ramakrishna BS, Shaji RV, et al. Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol. 2003;285:G177-G184.
114. Karaki S, Mitsui R, Hayashi H, et al. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res. 2006;324:353-360.
115. Masui R, Sasaki M, Funaki Y, et al. G protein-coupled receptor 43 moderates gut inflammation through cytokine regulation from mononuclear cells. Inflamm Bowel Dis. 2013;19:2848-2856.
116. Pacheco RG, Esposito CC, Muller LC, et al. Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis. World J Gastroenterol. 2012;18:4278-4287.
117. Oliveira AJ, Pinto Jünior FE, Formiga MC, et al. Comparison of prophylactic and therapeutic use of short-chain fatty acid enemas in diversion colitis: a study in Wistar rats. Clinics (Sao Paulo). 2010;65:1351-1356.
118. Vieira EL, Leonel AJ, Sad AP, et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem. 2012;23:430-436.
119. Hung TV, Suzuki T. Dietary fermentable fiber reduces intestinal barrier defects and inflammation in colitic mice. J Nutr. 2016;146:1970-1979.
120. Panasevich MR, Allen JM, Wallig MA, et al. Moderately fermentable potato fiber attenuates signs and inflammation associated with experimental colitis in mice. J Nutr. 2015;145:2781-2788.
121. Komiyama Y, Andoh A, Fujiwara D, et al. New prebiotics from rice bran ameliorate inflammation in murine colitis models through the modulation of intestinal homeostasis and the mucosal immune system. Scand J Gastroenterol. 2011;46:40-52.
122. Arribas B, Suarez-Pereira E, Mellet CO, et al. Di-D-fructose dianhydride-enriched caramels: effect on colon microbiota, inflammation, and tissue damage in trinitrobenzenesulfonic acid-induced colitic rats. J Agr Food Chem. 2010;58:6476-6484.
123. Wang H, Shi P, Zuo L, et al. Dietary non-digestible polysaccharides ameliorate intestinal epithelial barrier dysfunction in IL-10 knockout mice. J Crohns Colitis. 2016;10:1076-1086.
124. Takagi T, Naito Y, Higashimura Y, et al. Partially hydrolysed guar gum ameliorates murine intestinal inflammation in association with modulating luminal microbiota and SCFA. Br J Nutr. 2016;116:1199-1205.
125. Koleva PT, Valcheva RS, Sun X, et al. Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr. 2012;108:1633-1643.
126. D'Argenio G, Cosenza V, Delle Cave M, et al. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology. 1996;110:1727-1734.
127. Wong CS, Sengupta S, Tjandra JJ, et al. The influence of specific luminal factors on the colonic epithelium: high-dose butyrate and physical changes suppress early carcinogenic events in rats. Dis Colon Rectum. 2005;48:549-559.
128. Medina V, Afonso JJ, Alvarez-Arguelles H, et al. Sodium butyrate inhibits carcinoma development in a 1,2-dimethylhydrazine-induced rat colon cancer. JPEN J Parenter Enteral Nutr. 1998;22:14-17.
129. Freeman HJ. Effects of differing concentrations of sodium butyrate on 1,2-dimethylhydrazine- induced rat intestinal neoplasia. Gastroenterology. 1986;91:596-602.
130. Caderni G, Luceri C, De Filippo C, et al. Slow-release pellets of sodium butyrate do not modify azoxymethane (AOM)-induced intestinal carcinogenesis in F344 rats. Carcinogenesis. 2001;22:525-527.
131. Silva FG, Penido LC, Valente FX, et al. Sodium butyrate does not decrease the evolution of precancerous lesions in rats. Acta Cir Bras. 2010;25:507-512.
132. Gaschott T, Steinhilber D, Milovic V, et al. Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells. J Nutr. 2001;131:1839-1843.
133. Heidor R, Furtado KS, Ortega JF, et al. The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage. Toxicol Appl Pharmacol. 2014;276:129-135.
134. Deschner EE, Ruperto JF, Lupton JR, et al. Dietary butyrate (tributyrin) does not enhance AOM-induced colon tumorigenesis. Cancer Lett. 1990;52:79-82.
135. Clarke JM, Young GP, Topping DL, et al. Butyrate delivered by butyrylated starch increases distal colonic epithelial apoptosis in carcinogen-treated rats. Carcinogenesis. 2012;33:197-202.
136. Sivaprakasam S, Gurav A, Paschall AV, et al. An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis. Oncogenesis. 2016;5:e238. doi:10.1038/ oncsis.2016.38.
137. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;40:128-139.
138. Toden S, Lockett TJ, Topping DL, et al. Butyrylated starch affects colorectal cancer markers beneficially and dose-dependently in genotoxin-treated rats. Cancer Biol Ther. 2014;15:1515-1523.
139. Donohoe DR, Holley D, Collins LB, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 2014;4:1387-1397.
140. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117-129.
141. Rolandelli RH, Koruda MJ, Settle RG, et al. Effects of intraluminal infusion of short-chain fatty acids on the healing of colonic anastomosis in the rat. Surgery. 1986;100:198-204.
142. Bloemen JG, Schreinemacher MH, de Bruine AP, et al. Butyrate enemas improve intestinal anastomotic strength in a rat model. Dis Colon Rectum. 2010;53:1069-1075.
143. Mathew AJ, Wann VC, Abraham DT, et al. The effect of butyrate on the healing of colonic anastomoses in rats. J Invest Surg. 2010;23:101-104.
144. Aguilar-Nascimento JE, Mathie RT, Man WK, et al. Enhanced intra-anastomotic healing by operative lavage with nutrient solutions in experimental left-sided colonic obstruction. Br J Surg. 1995;82:461-464.
145. Topcu O, Karaday K, Kuzu MA, et al. Enteral and intraluminal short-chain fatty acids improves ischemic left colonic anastomotic healing in the rat. Int J Colorectal Dis. 2002;17:171-176.
146. Aguilar-Nascimento JE, Salomao AB, Nochi RJ Jr, et al. Intraluminal injection of short chain fatty acids diminishes intestinal mucosa injury in experimental ischemia- reperfusion. Acta Cir Bras. 2006;21:21-25.
147. Fa-Si-Oen P, van de Gender P, Putter H, et al. The effect of polyethylene glycol and butyrate on anastomotic healing in the rat colon. Tech Coloproctol. 2006;10:308-311.
148. Koruda MJ, Rolandelli RH, Bliss DZ, et al. Parenteral nutrition supplemented with short-chain fatty acids: effect on the small-bowel mucosa in normal rats. Am J Clin Nutr. 1990;51:685-689.
149. Koruda MJ, Rolandelli RH, Settle RG, et al. Effect of parenteral nutrition supplemented with short-chain fatty acids on adaptation to massive small bowel resection. Gastroenterology. 1988;95:715-720.
150. Rolandelli RH, Buckmire MA, Bernstein KA. Intravenous butyrate and healing of colonic anastomoses in the rat. Dis Colon Rectum. 1997;40:67-70.
151. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107:14691-14696.
152. Reijnders D, Goossens GH, Hermes GD, et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized doubleblind placebo-controlled trial. Cell Metabol. 2016;24:63-74.
153. Huda-Faujan N, Abdulamir AS, Fatimah AB, et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J. 2010;4:53-58.
154. Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol. 2013;19:3404-3414.
155. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011;60:631-637.
156. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275-1283.
157. Galecka M, Szachta P, Bartnicka A, et al. Faecalibacterium prausnitzii and Crohn's disease-is there any connection? Pol J Microbiol. 2013;62:91-95.
158. Renom G, Bulois P, Hafraoui S, et al. Simple gas chromatography analysis of faecal butyrate: application to patients at risk of pouchitis. Clin Chem Lab Med. 2001;39:15-19.
159. Sagar PM, Taylor BA, Godwin P, et al. Acute pouchitis and deficiencies of fuel. Dis Colon Rectum. 1995;38:488-493.
160. Clausen MR, Tvede M, Mortensen PB. Short-chain fatty acids in pouch contents from patients with and without pouchitis after ileal pouch-anal anastomosis. Gastroenterology. 1992;103:1144-1153.
161. Hove H, Mortensen PB. Short-chain fatty acids in the non-adapted and adapted pelvic ileal pouch. Scand J Gastroenterol. 1996;31:568-574.
162. Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouchanal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc. 1993;68:978-981.
163. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79. doi:10.1186/gb-2012-13-9-r79.
164. De Preter V, Bulteel V, Suenaert P, et al. Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa. Inflamm Bowel Dis. 2009;15:335-340.
165. Finnie IA, Taylor BA, Rhodes JM. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut. 1993;34:1552-1558.
166. Boesmans L, Ramakers M, Arijs I, et al. Inflammation-induced downregulation of butyrate uptake and oxidation is not caused by a reduced gene expression. J Cell Physiol. 2015;230:418-426.
167. Vernia P, Caprilli R, Latella G, et al. Fecal lactate and ulcerative colitis. Gastroenterology. 1988;95:1564-1568.
168. Vertzoni M, Goumas K, Soderlind E, et al. Characterization of the ascending colon fluids in ulcerative colitis. Pharm Res. 2010;27:1620-1626.
169. Lambert DW, Wood IS, Ellis A, et al. Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer. 2002;86:1262-1269.
170. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA. 2003;100:8412-8417.
171. Brown DG, Rao S, Weir TL, et al. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016;4:11. doi:10.1186/s40170-016-0151-y.
172. Burkitt DP. Epidemiology of cancer of the colon and rectum. Cancer. 1971;28:3-13.
173. O'Keefe SJ, Chung D, Mahmoud N, et al. Why do African Americans get more colon cancer than Native Africans? J Nutr. 2007;137(1 suppl):175S-182S.
174. Ou J, Carbonero F, Zoetendal EG, et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am J Clin Nutr. 2013;98:111-120.
175. Ou J, DeLany JP, Zhang M, et al. Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations. Nutr Cancer. 2012;64:34-40.
176. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688-1694.
177. Clausen MR, Bonnen H, Mortensen PB. Colonic fermentation of dietary fibre to short chain fatty acids in patients with adenomatous polyps and colonic cancer. Gut. 1991;32:923-928.
178. Weaver GA, Krause JA, Miller TL, et al. Short chain fatty acid distributions of enema samples from a sigmoidoscopy population: an association of high acetate and low butyrate ratios with adenomatous polyps and colon cancer. Gut. 1988;29:1539-1543.
179. Weir TL, Manter DK, Sheflin AM, et al. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013;8:e70803. doi:10.1371/journal.pone.0070803.
180. Bradburn DM, Mathers JC, Gunn A, et al. Colonic fermentation of complex carbohydrates in patients with familial adenomatous polyposis. Gut. 1993;34: 630-636.
181. Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci. 1991;36:185-187.
182. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol. 1994;89:179-183.
183. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, et al. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol. 1996;91: 731-734.
184. Vernia P, Cittadini M, Caprilli R, et al. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci. 1995;40: 305-307.
185. Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992;103:51-56.
186. Senagore AJ, MacKeigan JM, Scheider M, et al. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum. 1992;35:923-927.
187. Steinhart AH, Hiruki T, Brzezinski A, et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther. 1996;10:729-736.
188. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci. 1996;41:2254-2259.
189. Scheppach W, Muller JG, Boxberger F, et al. Histological changes in the colonic mucosa following irrigation with short-chain fatty acids. Eur J Gastroenterol Hepatol. 1997;9:163-168.
190. Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut. 1997;40:485-491.
191. Lührs H, Gerke T, Muller JG, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37:458-466.
192. Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest. 2003;33:244-248.
193. Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9:309-313.
194. Vernia P, Monteleone G, Grandinetti G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci. 2000;45:976-981.
195. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res. 2005;49:601-608.
196. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol. 1999;94: 427-433.
197. Martinez CA, de Campos FG, de Carvalho VR, et al. Claudin-3 and occludin tissue content in the glands of colonic mucosa with and without a fecal stream. J Mol Histol. 2015;46:183-194.
198. Korelitz BI, Cheskin LJ, Sohn N, et al. Proctitis after fecal diversion in Crohn's disease and its elimination with reanastomosis: implications for surgical management. Report of four cases. Gastroenterology. 1984;87:710-713.
199. Harig JM, Soergel KH, Komorowski RA, et al. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med. 1989;320:23-28.
200. Kiely EM, Ajayi NA, Wheeler RA, et al. Diversion procto-colitis: response to treatment with short-chain fatty acids. J Pediatr Surg. 2001;36:1514-1517.
201. Pal K, Tinalal S, Al Buainain H, et al. Diversion proctocolitis and response to treatment with short-chain fatty acids-a clinicopathological study in children. Indian J Gastroenterol. 2015;34:292-299.
202. Komorowski RA. Histologic spectrum of diversion colitis. Am J Surg Pathol. 1990;14:548-554.
203. Guillemot F, Colombel JF, Neut C, et al. Treatment of diversion colitis by shortchain fatty acids. Prospective and double-blind study. Dis Colon Rectum. 1991;34:861-864.
204. Schauber J, Bark T, Jaramillo E, et al. Local short-chain fatty acids supplementation without beneficial effect on inflammation in excluded rectum. Scand J Gastroenterol. 2000;35:184-189.
205. Luceri C, Femia AP, Fazi M, et al. Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: a randomized trial. Dig Liver Dis. 2016;48:27-33.
206. Mohammed N, Kestin L, Ghilezan M, et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiation Oncol Biol Physics. 2012;82:204-212.
207. Mamel JJ, Chen M, Combs W, et al. Short-chain fatty acids (SCFA) enemas are useful for the treatment of chronic radiation proctitis. Gastroenterology. 1995;108(suppl 1):A305. doi:10.1016/0016-5085(95)23880-8.
208. Al-Sabbagh R, Sinicrope FA, Sellin JH, et al. Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol. 1996;91:1814-1816.
209. Talley NA, Chen F, King D, et al. Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial. Dis Colon Rectum. 1997;40:1046-1050.
210. Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are effective in shortterm treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. Dis Colon Rectum. 1999;42:788-795; discussion 795-786.
211. Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet. 2000;356:1232-1235.
212. Hille A, Herrmann MK, Kertesz T, et al. Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation. Strahlenther Onkol. 2008;184: 686-692.
213. Maggio A, Magli A, Rancati T, et al. Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study. Int J Radiat Oncol Biol Phys. 2014;89:518-524.
214. Shadad AK, Sullivan FJ, Martin JD, et al. Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.World J Gastroenterol. 2013;19:185-198.
215. Tonelli F, Dolara P, Batignani G, et al. Effects of short chain fatty acids on mucosal proliferation and inflammation of ileal pouches in patients with ulcerative colitis and familial polyposis. Dis Colon Rectum. 1995;38:974-978.
216. Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002;45:621-627.
217. Di Sabatino A, Morera R, Ciccocioppo R, et al. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther. 2005;22:789-794.
218. Le Leu RK, Winter JM, Christophersen CT, et al. Butyrylated starch intake can prevent red meat-induced O6-methyl-2-deoxyguanosine adducts in human rectal tissue: a randomised clinical trial. Brit J Nutr. 2015;114:220-230.
219. van Munster IP, Tangerman A, Nagengast FM. Effect of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation. Dig Dis Sci. 1994;39:834-842.
220. Heijnen ML, van Amelsvoort JM, Deurenberg P, et al. Limited effect of consumption of uncooked (RS2) or retrograded (RS3) resistant starch on putative risk factors for colon cancer in healthy men. Am J Clin Nutr. 1998;67:322-331.
221. Dronamraju SS, Coxhead JM, Kelly SB, et al. Cell kinetics and gene expression changes in colorectal cancer patients given resistant starch: a randomised controlled trial. Gut. 2009;58:413-420.
222. Mathers JC, Movahedi M, Macrae F, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol. 2012;13:1242-1249.
223. O'Keefe SJ, Li JV, Lahti L, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342. doi:10.1038/ncomms7342.
224. Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA. 2005;294: 2849-2857.
225. Orlich MJ, Singh PN, Sabate J, et al. Vegetarian dietary patterns and the risk of colorectal cancers. JAMA Intern Med. 2015;175:767-776.
226. Triff K, Kim E, Chapkin RS. Chemoprotective epigenetic mechanisms in a colorectal cancer model: Modulation by n-3 PUFA in combination with fermentable fiber. Curr Pharmacol Rep. 2015;1:11-20.
227. Patnaik A, Rowinsky EK, Villalona MA, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res. 2002;8:2142-2148.
228. Conley BA, Egorin MJ, Tait N, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res. 1998;4:629-634.
229. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2002;8:963-970.
230. Thibault A, Cooper MR, Figg WD, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 1994;54:1690-1694.
231. Thibault A, Samid D, Cooper MR, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 1995;75:2932-2938.
232. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001;7:2292-2300.
233. Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004;45:381-386.
234. Ram E, Sherman Y, Weil R, et al. Is mechanical bowel preparation mandatory for elective colon surgery? A prospective randomized study. Arch Surg. 2005;140:285-288.
235. Miettinen RP, Laitinen ST, Makela JT, et al. Bowel preparation with oral polyethylene glycol electrolyte solution vs. no preparation in elective open colorectal surgery: prospective, randomized study. Dis Colon Rectum. 2000;43:669-675; discussion 675-667.
236. Burke P, Mealy K, Gillen P, et al. Requirement for bowel preparation in colorectal surgery. Br J Surg. 1994;81:907-910.
237. Russo F, Linsalata M, Clemente C, et al. Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers. Nutr Res. 2012;32:940-946.
238. Hamer HM, Jonkers DM, Renes IB, et al. Butyrate enemas do not affect human colonic MUC2 and TFF3 expression. Eur J Gastroenterol Hepatol. 2010;22:1134-1140.
239. Hamer HM, Jonkers DM, Bast A, et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr. 2009;28:88-93.
240. Mortensen FV, Langkilde NC, Joergensen JC, et al. Short-chain fatty acids stimulate mucosal cell proliferation in the closed human rectum after Hartmann's procedure. Int J Colorectal Dis. 1999;14:150-154.
241. Wedlake L, Slack N, Andreyev HJ, et al. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. Inflamm Bowel Dis. 2014;20:576-586.
242. Assisi RF, GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol. 2008;54:231-238.
243. Leek BT, Tasto JP, Tibor LM, et al. Augmentation of tendon healing with butyric acid-impregnated sutures: biomechanical evaluation in a rabbit model. Am J Sports Med. 2012;40:1762-1771.